A086460 Stock Overview
Curable. Inc. provides single nucleotide polymorphism (SNP) research and analysis services in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Curable. Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,820.00 |
| 52 Week High | ₩10,070.00 |
| 52 Week Low | ₩3,655.00 |
| Beta | 0 |
| 1 Month Change | 0.42% |
| 3 Month Change | -12.36% |
| 1 Year Change | -41.22% |
| 3 Year Change | -33.97% |
| 5 Year Change | -6.95% |
| Change since IPO | -12.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| A086460 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -7.3% | -5.0% | -4.3% |
| 1Y | -41.2% | -3.5% | -1.0% |
Return vs Industry: A086460 underperformed the KR Biotechs industry which returned -3.5% over the past year.
Return vs Market: A086460 underperformed the KR Market which returned -1% over the past year.
Price Volatility
| A086460 volatility | |
|---|---|
| A086460 Average Weekly Movement | 18.8% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 12.0% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A086460's share price has been volatile over the past 3 months.
Volatility Over Time: A086460's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Hyoung-Doo Shin | curablent.com |
Curable. Inc. provides single nucleotide polymorphism (SNP) research and analysis services in South Korea. The company offers various services, such as genome analyzer; and sequencing and re-sequencing, immunoprecipitate sequencing, small RNA discovery and analysis, and digital gene expression profiling services.
Curable. Inc. Fundamentals Summary
| A086460 fundamental statistics | |
|---|---|
| Market cap | ₩16.67b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A086460 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A086460 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A086460 perform over the long term?
See historical performance and comparison